Disease · MONDO_0010030
Sjogren syndrome
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. Sjogren syndrome. Diseases, record MONDO_0010030. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0010030
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Mikulicz disease, SJOGREN'S SYNDROME, Sicca (Sjogren's) syndrome, Sicca syndrome (disorder), Sjgren's syndrome (disorder), Sjogren's disease, Sjogren's syndrome (disorder), Sjogrens Syndrome, Sjögren syndrome, Sjögren-Gougerot syndrome, Syndrome, Sicca, primary Sjogren-Gougerot syndrome, primary Sjögren-Gougerot syndrome, sicca syndrome, syndrome, Sjogren's, xerodermosteosis
- Open Targets
Drugs74
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| PILOCARPINE | CHEMBL550 | Small molecule | Approval | DailyMed | 2 | 1 | 1 | Drugs and targets |
| BROMHEXINE | CHEMBL253376 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| CEVIMELINE | CHEMBL168815 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| IANALUMAB | CHEMBL4594357 | Antibody | Phase 3 | ClinicalTrials.gov | 10 | 9 | 9 | Drugs and targets |
| DAZODALIBEP | CHEMBL4594331 | Protein | Phase 3 | ClinicalTrials.gov | 7 | 4 | 4 | Drugs and targets |
| ABATACEPT | CHEMBL1201823 | Protein | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| NIPOCALIMAB | CHEMBL4594310 | Antibody | Phase 3 | ClinicalTrials.gov | 3 | 2 | 2 | Drugs and targets |
| ARSENIC | CHEMBL1231052 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| DEUCRAVACITINIB | CHEMBL4435170 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EPRATUZUMAB | CHEMBL2108404 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 74
See all 74 drugsTargets55
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PIK3CD | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | 4 | PI3-kinase p110-delta subunit inhibitor | Phase 2 | https://conductscience.org/library/genes/5293 | Drugs and targets |
| CSF3R | Granulocyte colony-stimulating factor receptor | 3 | Granulocyte colony stimulating factor receptor agonist | Phase 1 | https://conductscience.org/library/genes/1441 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 3 | Glucocorticoid receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| TYK2 | Janus Kinase (JAK) | 3 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase TYK2 negative allosteric modulator | Phase 3 | https://conductscience.org/library/genes/7297 | Drugs and targets |
| BTK | Tyrosine-protein kinase BTK | 2 | Tyrosine-protein kinase BTK inhibitor | Phase 2 | https://conductscience.org/library/genes/695 | Drugs and targets |
| CHRM1 | Muscarinic acetylcholine receptor M1 | 2 | Muscarinic acetylcholine receptor M1 agonist | Approval | https://conductscience.org/library/genes/1128 | Drugs and targets |
| CHRM3 | Muscarinic acetylcholine receptor M3 | 2 | Muscarinic acetylcholine receptor M3 agonist | Approval | https://conductscience.org/library/genes/1131 | Drugs and targets |
| FCGRT | IgG receptor FcRn large subunit p51 | 2 | IgG receptor FcRn large subunit p51 antagonist | Phase 3 | https://conductscience.org/library/genes/2217 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 2 | FK506-binding protein 1A inhibitor | Phase 2/3 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| IMPDH1 | Inosine-5'-monophosphate dehydrogenase (IMPDH) | 2 | Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor | Phase 2 | https://conductscience.org/library/genes/3614 | Drugs and targets |
1 to 10 of 55
See all 55 targetsTrials80
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01261793 | Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) | Phase 3 | 791 | 2018-06-29 | Systemic Lupus Erythematosus | EPRATUZUMAB | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT02915159 | A Study to Assess the Efficacy and Safety of Abatacept in Adults With Active Primary Sjögrens Syndrome | Phase 3 | 250 | 2020-01-02 | Sjogrens Disease | ABATACEPT | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04541589 | Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome | Phase 2 | 206 | 2025-06-29 | Sjogren's Syndrome | ISCALIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04129164 | A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome | Phase 2 | 183 | 2025-04-30 | Sjögren's Syndrome | DAZODALIBEP | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT03100942 | Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome | Phase 2 | 152 | 2020-01-22 | Sjogren's Syndrome | FILGOTINIB, LANRAPLENIB, TIRABRUTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT04186871 | Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis | Phase 2 | 119 | 2024-01-16 | Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sjögren's Syndrome | ABATACEPT, BRANEBRUTINIB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04572841 | Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS) | Phase 2 | 84 | 2025-10-09 | Sjögren's Syndrome, Sjogren's Syndrome | FREXALIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04035668 | A Phase 2 Study to Evaluate the Safety and Efficacy of LOU064 in Patients With Moderate to Severe Sjögren's Syndrome | Phase 2 | 73 | 2022-12-20 | Sjögren Syndrome | REMIBRUTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02291029 | Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome | Phase 2 | 69 | 2019-08-14 | Primary Sjögren's Syndrome | ISCALIMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01552681 | Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome | Phase 2 | 52 | 2016-03-23 | Primary Sjögren's Syndrome | BAMINERCEPT | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
1 to 10 of 80
See all 80 trialsComparisons in its trials22
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Arm 1: Iscalimab 600 mg vs Arm 2 - Iscalimab 300 mg: Incidence of Anti-iscalimab Antibodies in Plasma | 1 of 152 | 2 of 54 | 206 | NCT04541589 | Trial comparisons |
| Arm 1: Iscalimab 600 mg vs Arm 2 - Iscalimab 300 mg: deaths from any cause | 0 of 152 | 0 of 54 | 206 | NCT04541589 | Trial comparisons |
| Arm 1: Iscalimab 600 mg vs Arm 2 - Iscalimab 300 mg: serious adverse events | 13 of 152 | 2 of 54 | 206 | NCT04541589 | Trial comparisons |
| Population 2: VIB4920 vs Population 2: Placebo: Population 2: Number of Participants Who Achieved ESSPRI Response at Day 169 | 36 of 54 | 18 of 55 | 109 | NCT04129164 | Trial comparisons |
| SAR441344 vs Placebo: deaths from any cause | 0 of 42 | 0 of 42 | 84 | NCT04572841 | Trial comparisons |
| SAR441344 vs Placebo: serious adverse events | 1 of 42 | 1 of 42 | 84 | NCT04572841 | Trial comparisons |
| Baminercept 100 mg vs Placebo: serious adverse events | 5 of 33 | 1 of 19 | 52 | NCT01552681 | Trial comparisons |
| DNase vs Vehicle: deaths from any cause | 0 of 25 | 0 of 22 | 47 | NCT02193490 | Trial comparisons |
| DNase vs Vehicle: serious adverse events | 0 of 25 | 0 of 22 | 47 | NCT02193490 | Trial comparisons |
| Any MEDI5872 210 mg vs Placebo: Number of Participants With Adverse Events of Special Interest (AESIs) | 6 of 31 | 1 of 16 | 47 | NCT02334306 | Trial comparisons |
1 to 10 of 22
See all 22 comparisons in its trialsPapers from its trials39
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0010030
GET https://conductscience.org/api/diseases/v1/MONDO_0010030/drugs?page=2